2019 Rubella (German Measles) R&D Pipeline Drugs, Companies, Trials and Developments

March 2019 | 40 pages | ID: 2EB6C172050EN
VPAResearch

Abstracts

The global demand for Rubella (German Measles) treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Rubella (German Measles) are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Rubella (German Measles) pipeline companies from advancing their products.
Rubella (German Measles) Report Description
The H1-2019 pipeline review report on Rubella (German Measles) is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.
The Rubella (German Measles) pipeline guide presents information on all active drugs currently being developed for Rubella (German Measles). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Rubella (German Measles) pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Rubella (German Measles) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Rubella (German Measles) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Rubella (German Measles) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Rubella (German Measles) pipeline report includes-

• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds
• For each pipeline product, the following details are provided-
• Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Rubella (German Measles) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Rubella (German Measles) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Rubella (German Measles) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

GLOBAL RUBELLA (GERMAN MEASLES) PIPELINE OVERVIEW

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

EXECUTIVE SUMMARY

Rubella (German Measles) Drugs under active development, H1@2019
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
Companies involved in Rubella (German Measles) pipeline, H1@2019
Mechanism of Action wise Rubella (German Measles) Pipeline Candidates

BIOLOGICAL E LIMITED RUBELLA (GERMAN MEASLES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

CADILA HEALTHCARE LTD RUBELLA (GERMAN MEASLES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

GLAXOSMITHKLINE PLC RUBELLA (GERMAN MEASLES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

INDIAN IMMUNOLOGICALS LTD RUBELLA (GERMAN MEASLES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

JAPAN VACCINE CO LTD RUBELLA (GERMAN MEASLES) PIPELINE DETAILS

Business Profile
Drug Details
  Drug Snapshot
  Originator
  Collaborator/Co-Developer
  Route of Administration
  Orphan Drug/Fast Track/Special Designation
  Area
  Type of Molecular Entity
Current Status
Drug Overview
Drug Mechanism of Action
Clinical/Pre-clinical Trial Details
Latest Drug Developments

LATEST RUBELLA (GERMAN MEASLES) DRUG PIPELINE DEVELOPMENTS, 2019

APPENDIX

About Us
Sources and Methodology
Contact Information